AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2025

Jun 12, 2025

30610_dirs_2025-06-12_ee680b04-a375-4927-abea-edc602c35501.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-06-11

Reporting Person: Hussain Abbas (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-11	Common Stock	S	312	$28.00	Disposed	580	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.